FAREVA is France’s largest CMO and ranks in the top five of Pharmaceutical Contract Manufacturing Organizations in the world. The company has 40 production sites, over 12,5000 employees and generated over €1.6 billion in sales in 2018.

FAREVA’s Drug Substance Manufacturing performs cGMP manufacturing of small molecule APIs from 1 kg to 250 MT. FAREVA API manufacturing has three locations (FAREVA - Excella, FAREVA – Valdepharm, FAREVA – La Vallée) supporting drug substance manufacturing for both clinical trials and commercial production. Fareva has a broad range of capacity with reactors ranging from 25 L to 10,000 L. The company has niche technology for spray drying, aseptic crystallization, aseptic micronization, hormones, high pressure hydrogenation, and highly potent manufacturing and micronization. FAREVA is the first and only company in the world to receive SafeBridge® Certification to handle both high potent drug substance and drug product at the same facility.

FAREVA’s facilities are FDA inspected and the company has an excellent track record and experience with regulatory agencies worldwide.

Three Locations

Nürnberger Str. 12
D-90537 Feucht
Parc Industriel d'Incarville, CS10606
F-27106 Val De Reuil CEDEX
Fareva La Vallée
928, avenue Lavoisier
43700 Saint-Germain-Laprade



Fareva offers a large range of aseptic CDMO services in their Valdepharm facility.

Fareva offers several spray drying capabilities in their Valdepharm facility.

Fareva offers a one stop shop opportunity for your oral solid dosage, high potent OSD, and sterile injectable needs.

Fareva offers a large scope of high potent manufacturing capabilities across two different facilities.

Fareva offers a broad range of CDMO manufacturing services and facilities for your drug substance manufacturing needs.



Nürnberger Str. 12

Feucht, D-90537


Phone: 919-768-6858 (U.S.)

Contact: George Hlass


  • Innovative Approach To Process Development

    The key to successful development of safe, efficient, and cost-effective active pharmaceutical ingredient (API) production-scale processes is the application of smart chemistry and process development principles that include convergent strategies, telescoping, and open-mindedness.

  • A Successful Approach For Managing Unexpected Increases In Potency For HPAPIs

    CDMOs face the challenge of managing new APIs in development projects with incomplete toxicity and pharmacology data. When a development project initially classified as an occupational exposure band (OEB)-4 highly potent API (HPAPI) had been later reclassified as an OEB-6 compound, the company upgraded a state-of-the-art containment production line to ensure operator safety and keep the project on track in less than one year.

  • Fareva Continues To Purchase Production Sites For Sterile Manufacturing

    On 9. July 2020, an agreement was reached with the Pierre-Fabre group for Fareva acquiring two pharmaceutical sterile manufacturing sites, that we expect to assume operation by year end.

  • Simplifying The Supply Chain With Large-Volume Western CDMO Partners

    When considering primary and secondary sourcing options, it is important to balance price and security of supply. Partnering with an integrated, Western CDMO with large-volume production capabilities for registered starting materials (RSMs), advanced intermediates, and active pharmaceutical ingredients (APIs) can provide countless advantages, including reliability and superior communication, at a competitive cost.

  • Providing Solutions At Fair Value: A Spray Drying Case Study

    Pharmaceutical companies need CDMO partners that provide solutions at fair value. This CMO has a long history of investing in new technologies with innovators to help their customers achieve their goals, and one recent example is the construction of a new Hastelloy spray-drying unit.

  • Expanding Sterile Crystallization Capabilities To Meet Rising Customer Demand

    Production of sterile powders requires specialized expertise and capabilities in sterile crystallization. Learn what your CDMO capabilities should be in order to deliver a quality product.

  • Why Choose A Commercial HPAPI Manufacturer For Your Clinical Program?

    Switching from an early-phase CDMO to a commercial-scale manufacturer for your highly potent active pharmaceutical ingredient (HPAPI) projects can be costly and lead to project delays.


  • Fareva’s New High Potent API Facility – Video Tour

    Fareva has invested $30M in a new HPAPI facility. The investment adds a 2nd HPAPI site to the Fareva network and more than doubles Fareva’s capacity for HPAPIs. In this video, you will see both the pilot and large scale HPAPI manufacturing at the Fareva La Vallée site.

  • Fareva HPAPI Building Construction

    In August 2018, Fareva completed the construction of their $30M new HPAPI facility at the Fareva La Vallée site. In this video you will see a time lapse view of the construction of the highly potent API facility.

  • Fareva La Vallée

    Fareva La Vallee, 30 Years of experience on a wide range of processes. This video includes commentary from corporate management, chemistry, health safety and the environment, technical, Logistics, production, quality control and regulatory. Hopefully watching this video will give you a good feel of who we are and will create the desire to know us better.